Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 2Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 38Cyclophosphamide 37Peripheral Blood Stem Cell Transplantation 32Busulfan 28Tacrolimus 26Whole-Body Irradiation 20Mycophenolic Acid 19Methotrexate 17Antilymphocyte Serum 17ruxolitinib 16fludarabine 14Filgrastim 13Cyclosporine 12Melphalan 11Radiotherapy 9Etoposide 9thymoglobulin 8Psychiatric Rehabilitation 8Prednisone 8Methylprednisolone 8Cytarabine 6Cord Blood Stem Cell Transplantation 6Thiotepa 5Sirolimus 5Imatinib Mesylate 5Flow Cytometry 5Azacitidine 5Alemtuzumab 5sargramostim 4merphos 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Myelofibrosis × GRN163L peptide × Clear all
NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Geron Corporation

Phase 2 Completed
80 enrolled 31 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡